BioSpace News Archive

Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2022.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial Officer.

Amarin Corporation plc announced an exploratory post hoc sub-analysis of REDUCE-IT serum samples that found statin-treated patients allocated to icosapent ethyl had limited differences in certain lipid and inflammatory biomarkers compared with statin-treated patients allocated to mineral oil placebo.

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), announced today the establishment of a Scientific Advisory Board (SAB) of renowned experts in their respective fields to provide scientific and clinical guidance on the development of Affimed’s innate cell engagers (ICE®) programs.

Provention Bio, Inc. (Nasdaq: PRVB) (the “Company”), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended its review period by three months for the Biologics License Application (BLA) for teplizumab.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd. (Otsuka).

DexCom, Inc. announced that it plans to release its second quarter 2022 financial results after market close on Thursday, July 28, 2022.

ZAP Surgical Systems, Inc., developer and manufacturer of the ZAP-X® surgical robot for non-invasive ablation of brain tumors, announced that the Chairman of Foxconn Technology Co Ltd, Lu Jun-Fu, has joined the ZAP Surgical Board of Directors.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced July conference presentations.

The Public Health Agency of Canada continues to monitor COVID-19 epidemiological indicators to quickly detect, understand and communicate emerging issues of concern.